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Abstract
Background: Zinc is emerging as an important intracellular signaling molecule, as well as fulfilling essential structural and
catalytic functions through incorporation in a myriad of zinc metalloproteins so it is important to elucidate the molecular
mechanisms of zinc homeostasis, including the subcellular localizations of zinc transporters.
Principal Findings: Two splice variants of the human SLC30A5 Zn transporter gene (ZnT5) have been reported in the
literature. These variants differ at their N- and C-terminal regions, corresponding with the use of different 59 and 39 exons.
We demonstrate that full length human ZnT5 variant B is a genuine transcript in human intestinal cells and confirm
expression of both variant A and variant B in a range of untreated human tissues by splice variant-specific RT-PCR. Using N-
or C-terminal GFP or FLAG fusions of both isoforms of ZnT5 we identify that the differential subcellular localization to the
Golgi apparatus and ER respectively is a function of their alternative C-terminal sequences. These different C-terminal
regions result from the incorporation into the mature transcript of either the whole of exon 14 (variant B) or only the 59
region of exon 14 plus exons 15–17 (variant A).
Conclusions: We thus propose that exons 15 to 17 include a signal that results in trafficking of ZnT5 to the Golgi apparatus
and that the 39 end of exon 14 includes a signal that leads to retention in the ER.
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Introduction
Zinc is an essential micronutrient with widespread roles in
human health, resulting from the prevalence of zinc-containing
proteins (comprising 3–10% of the human genome) [1] with
diverse functions. Recent studies provide evidence that extracel-
lular stimuli can affect intracellular free zinc concentrations,
including through a rapid release of stored intracellular zinc – the
‘‘zinc wave’’ – with effects on cell function [2,3,4]. Zinc is thus
emerging as novel intracellular second messenger. It is therefore
important to elucidate the molecular mechanisms of mammalian
zinc homeostasis.
Zinc cannot pass through biological membranes by simple
passive diffusion and therefore zinc transport proteins are essential
to mediate cellular zinc uptake and efflux as well as intracellular
zinc sequestration to maintain cellular zinc homesostasis. Mem-
brane transport proteins with zinc transport capacity comprise two
major, families classified as SLC30 (ZnT family) and SLC39 (ZIP
family). In general, ZnT family proteins mediate cellular zinc
efflux or intracellular sequestration within membrane-bound
compartments/organelles while ZIP family proteins operate in
the opposite direction [5]. However, there are clearly examples of
proteins in both families that can operate either bi-directionally or
counter to the usual direction for other family members [6,7,8].
To date 10 ZnT proteins and 14 ZIP proteins have been identified
in humans, and the expression and localization of each varies
depending upon the cell type.
Two splice variants of the human SLC30A5 Zn transporter gene
(ZnT5) have been reported in the literature [9,10]. The sequences
reported differ at their N- and C-terminal regions, corresponding
with the use of different 59 and 39 exons [11] and (Figure 1A). The
ZnT5 splice variants adopted different subcellular localizations
when expressed as fusions to GFP from the corresponding
transgenes introduced into Chinese hamster ovary cells. Variant
A was expressed in the Golgi apparatus whereas variant B was
expressed throughout the cell, including at the plasma membrane
[11]. Plasma membrane localization of variant B, specifically
localization at the apical membrane, has also been observed in
human intestinal Caco-2 cells [9], and we have also reported
previously localization of ZnT5 to the apical enterocyte membrane
in human small intestine, using an antibody that may potentially
recognize both splice variants [12]. There has been a suggestion
PLoS ONE | www.plosone.org 1 August 2011 | Volume 6 | Issue 8 | e23878that expression levels of ZnT5 variant B are low or that the
transcript can be detected only after stimulation in specific cell
types, based on an observation that, under certain conditions,
variant B cDNA was difficult to generate by RT-PCR and on
observations that variant B is not found in any mRNA/cDNA
databases [13]. Here, full length ZnT5 variant B is confirmed as a
Figure 1. Schematic diagram depicting the ZnT5 gene and the combinations of exons comprising variants A and B and illustrating
the fusions and truncated protein constructs of ZnT5 generated. (A) The ZnT5 gene consists of 17 exons, all (with the exception of the 59end
of exon 3 and the 39 end of exon 14) are included in the mRNA for variant A. Exclusion of exons 1, 2, 4 and 15–17, plus inclusion of the 59end of exon
3 and the 39 end of exon 14, gives rise to variant B mRNA. A single primer that leads to PCR amplification of both variants anneals to sequence within
exon 13. Reverse primers anneal to the unique 39 ends of variant A and variant B. Black arrows indicate primers. (B). Diagram illustrating fusion and
truncated protein constructs of ZnT5. The grey box represents the region of identity between variants A and B. The white boxes represent regions
specific to variant A. Black boxes represent regions specific to variant B. Location of the GFP tag at the N- or C- terminus is shown. Numbering
corresponds to amino acids in either variant A or variant B and shows points of divergence between the two isoforms. All constructs were also made
with FLAG epitope tags.
doi:10.1371/journal.pone.0023878.g001
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standard conditions for 24 hours, using simple RT-PCR based
techniques. Furthermore, using primers specific to the unique 39
sequences in both variant A and variant B, expression of both
isoforms is confirmed in a range of untreated human tissues by
RT-PCR.
The targeting sequences and mechanisms responsible for the
differential subcellular localization of the two ZnT5 variants have
yet to be defined. Recent evidence suggests that the (predicted)
cytosolic C-terminal tail of ZnT5 variant A is important for
heterodimerisation with the zinc transporter ZnT6. These studies
indicated that the N-terminal region of ZnT5 is not involved in
the interaction with ZnT6, based on co-localization with ZnT6 to
a vesicular compartment of ZnT5 expressed with an N-terminal
deletion [13]. To investigate the potential role of the different N-
and C- terminal domains of the ZnT5 splice variants in
differential subcellular localisaton, we created a series of tagged
ZnT5 constructs; these constructs varied in the position of the tag
(N-terminal, C-terminal) and the tag identity (GFP or FLAG
epitope) and in the presence or absence of the splice variant-
specific N- and C-terminal regions of the protein (Figure 1B). We
examined the localization of each expressed fragment in Hela
cells, HEK293 cells and Caco-2 cells. Subcellular localizations
were consistent in all cell models and were not affected by the
nature of the fused protein tag. Images revealing patterns of
subcelluar localization herein are shown for GFP constructs only,
expressed in Hela cells.
Results
Given that questions have been raised about the existence of a
splice variant of ZnT5, designated ZnT5 variant B [13], we sought
to explore further the representation of the corresponding mRNA
species in total RNA extracted from human intestinal Caco-2 cells
and from a range of human tissues. Our previous data revealing
the ubiquitous existence of ZnT5 splice variant B in a variety of
human tissues relied on northern blotting and use of either a
variant A-specific or non-variant-specific probe [11] (A probe that
hybridises only to the unique sequence regions of variant B could
not be generated). We thus generated PCR primers specific to the
individual ZnT5 splice variants to confirm the existence of both.
Use in RT-PCR of primers designed to amplify specifically full-
length ZnT5 variant B mRNA resulted in a product of the
expected size (1569 bp) from total RNA extracted from human
intestinal Caco-2 cells grown for 24 hours under standard
conditions, which does not promote polarisation (Figure 2A).
Sequencing revealed identity to the expected product. The
nucleotide sequence has been submitted to the GenBank
TM/EBI
Data Bank with accession number JF802034. These data confirm
the existence and expression of ZnT5 variant B in Caco-2 cells
under the cell culture conditions employed.
Figure 2. Expression of splice variants of ZnT5 detected by RT-PCR. (A) Variant B is a genuine transcript of the ZnT5 gene. Product
corresponding to a full-length ZnT5 variant B mRNA (1569 bp, lane 1) was generated by RT-PCR from total RNA extracted from human intestinal
Caco-2 cells grown for 24 hours under standard conditions, which does not promote polarisation. Identity to the expected product was confirmed by
sequencing. Molecular weight markers with sizes indicated shown (lane M). (B) Tissue-specific RT-PCR carried out using primers designed to anneal to
the unique 39 end of variant A (exons 13–17) and variant B (exons 13–14
39) in a multiple tissue RNA panel (Ambion) revealed ubiquitous expression of
both transcripts. Identity to the expected products was confirmed by sequencing. Negative control RT-PCR reactions identical to those yielding the
products shown except for the omission of Moloney murine leukemia virus reverse transcriptase generated no products. Control reactions for all
samples using primers to GAPDH [11] were including to control for input (results not shown).
doi:10.1371/journal.pone.0023878.g002
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unique 39 end of variant A (exons 13–17) and variant B (exons 13–
14
39) carried out on a multiple tissue RNA panel (Ambion)
revealed ubiquitous expression of both transcripts, whose identity
to the expected products was confirmed by sequencing. The
varying intensities of bands in both panels indicates that the PCR
had not reached saturation and therefore we have been able to
compare different tissues with respect to their relative ratio of
variant B to variant A. (Comparison of absolute ratios cannot be
achieved because the different primer pairs used to generate
products may have resulted in different amplification efficiencies).
Levels of the transcripts differed between different tissues, as
already reported [10,11], (Figure 2B). Compared with other
tissues, we observed that RNA from bladder contained a notably
higher relative ratio of ZnT5 variant B to variant A, with a similar,
though less marked, relationship also observed for brain, heart and
adipose tissue. Along with our previous analyses [11], these data
demonstrate robustly that ZnT5 splice variant B is a genuine
transcript of the SLC30A5 gene.
Previous reports of the subcellular localization of ZnT5 based
on the use of antibodies with the potential to cross-react with both
variants [10,12] have identified subcellular localization to either
the Golgi apparatus in HEK293 cells [10] or apical enterocyte
membrane in the intestine [12]. Further, evidence based on
transient expression of either variant A or variant B conjugated to
marker proteins at the C-terminus revealed, for variant A,
localization to the Golgi apparatus [11] or the plasma membrane
in unpermeabilized Caco-2 cells [8] and, for variant B, diffuse
localization, including co-localization with wheat germ agglutinin
staining, in unpermeabilized CHO cells, indicating some locali-
zation at the plasma membrane [11]. To elucidate more fully the
localization of the splice variants of ZnT5, we generated constructs
including both N- and C- terminal GFP and FLAG epitope tags
and visualized the expression of the recombinant protein in three
different cell types: HeLa, HEK293 and Caco-2. The pattern of
localization did not vary with cell type or with identity of the tag,
thus for clarity we show here only data for HeLa cells expressing
GFP-tagged proteins. Data based on the use of FLAG-tagged
constructs are shown in the Figure S1.
Expression of ZnT5 variant A with a C- terminal GFP tag
(Figure 1B i) in permeabilized HeLa cells confirmed localization
at the Golgi apparatus, as reported previously [10,11]; Figure 3A
i. This construct did not co-localize with Rh-labelled ER Tracker
(results not shown), so does not localize to the ER. GFP fused to
the C-terminal region of ZnT5 splice variant B (Figure 1B v)
showed co-localization with a Rh-labelled ER Tracker in
permeabilized Hela cells, consistent with localization to the
endoplasmic reticulum (ER) (Figure 3A ii). This construct did not
co-localize with Rh-labelled WGA (results not shown), so does not
localize to the Golgi apparatus. GFP–only control showed a
diffuse pattern of expression throughout the cell in all
experiments (Figure 3A iii), confirming that localization of the
signal to specific subcellular regions was a function of the
attached ZnT5 protein or protein fragment. Further assurance
that observed patterns of localization did not reflect any property
or function of the GFP tag was provided by the observation that,
as already noted, identical patterns of localization were obtained
using equivalent constructs but with proteins tagged with the
FLAG epitope, detected using anti-FLAG antibody. For all
constructs, there was no alteration in the pattern of localization in
response to changing the extracellular zinc concentration for 24 h
immediately prior to viewing the cells either by adding ZnCl2 to
150 mM or adding the membrane-permeable zinc chelator TPEN
(5 mM) (data not shown); thus, we find no evidence for zinc-
induced intracellular trafficking of either variant of ZnT5,
consistent with previous observations [11].
To seek further confirmation that ZnT5 variant B is expressed
at the membrane of the ER, we made use of the fact that
localization of the zinc transporter ZIP7 to the ER is well-
established [14]. Cells were co-transfected with the construct
driving expression of ZnT5 variant B conjugated at the N-
terminus to GFP with a construct driving expression of ZIP7 with
a C-terminal V5 epitope tag, which was detected using anti-V5
monoclonal antibody followed by an anti-mouse IgG secondary
polyclonal antibody conjugated to AlexaFluor 594. The GFP and
AlexaFluor 594 signals showed clear co-localization (Figure 3B),
demonstrating that both zinc transporters are expressed at the
same subcellular membrane.
Intriguingly, and in contrast to the pattern of expression we
observed with GFP fused to the C-terminus (Golgi apparatus),
localization of variant A expressed with GFP fused to the N-
terminus (Figure 1B ii) was observed at the ER, confirmed by co-
localization with ER Tracker (Figure 4A i). The presence of an N-
terminal cleavage site could explain this pattern of localization
based on a model in which a mature, cleaved peptide trafficks to
the Golgi apparatus, while the cleaved N-terminal fragment is
retained in the ER. Consistent with this theory, Western blot
analysis using an anti-GFP antibody revealed a protein band of
approximately 70–80 KDa in total protein extract from HeLa cells
transfected with the construct from which ZnT5 variant A was
expressed fused at the C-terminus to GFP, consistent with a
cleaved product size (expected size of the un-cleaved fusion protein
(including GFP) 111 KDa). In further support of this model, a
protein product of approximately 55 KDa was revealed by anti-
GFP antibody on a Western blot of total protein extract from
HeLa cells transfected with the construct from which ZnT5
variant A was expressed fused at the N-terminus to GFP. A further
faint band of 111 KDa, consistent with the presence of some
residual, uncleaved protein, was also observed (Figure 4B).
In contrast to the differential patterns of localization observed
for ZnT5 variant A, depending on the position of the GFP or
FLAG tag, ZnT5 variant B localization to the ER was
independent of whether the GFP or FLAG tag was on the N- or
C-terminus (Figure 1Bvi; Figure 4A ii), consistent with a model in
which either the variant B peptide does no undergo any cleavage
or where both sections of a cleaved product localize to the ER.
Based on the observation that the two alternative transcripts of
ZnT5 incorporate different C-terminal regions, corresponding
with the use of different 39exons [11], we hypothesized that
differential localization may be dependent on this region. To test
this hypothesis we generated two constructs of ZnT5, one for
expression of only the region of the protein that is common to both
variants A and B (amino acids 172–666, according to residue
numbering for variant A) with a C-terminal GFP tag (Figure 1B iii)
and one lacking the histidine rich region common to both variants
and also lacking Asp599, which has been shown to be involved in
zinc binding in variant A [15] (amino acids 172–524, according to
residue numbering for variant A) with a C-terminal GFP tag
(Figure 1B iv). Use of the ‘core’ ZnT5 construct (amino acids 172–
666, Figure 1B iii) revealed localization to the ER, however a
punctuate/vesicular staining pattern was also observed, not seen
with either full length version of ZnT5 (Figure 5i). Use of the
shorter construct lacking the histidine rich region and Asp599
(amino acids 172–524, Figure 1B vi) revealed no localization of
ZnT5 to the Golgi apparatus or the ER (no co-localization with
WGA or ER Tracker dye) and a diffuse pattern of localization
similar to that observed on transfection with a plasmid from which
GFP was expressed without any protein fusion (negative control)
Differential Subcellular Localization of ZnT5
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which the region including amino acids 525 to 666, encompassing
the histidine-rich region, is required for retention within the system
of membranes that comprise the ER and Golgi apparatus, and in
which the variant A-specific C-terminal region, but not the variant
B-specific C-terminal region, directs trafficking of the protein to
the Golgi apparatus (probably following cleavage to remove a
signal peptide at the N-terminal region). This model was further
confirmed using an N-terminal deletion (amino acids 1–171)
construct of variant A (comprising amino acids 172–765) with a C-
terminal GFP tag. This construct had an identical pattern of
expression to full length variant A tagged at the C-terminus with
GFP (i.e. Golgi localization), (result not shown). Of possible
relevance to retention of ZnT5 variant B in the ER, a motif very
close to a consensus ER retention motif (consensus K (K/Q) XX,
when comprising the 4 C-terminal-most amino acid residues)
specific to variant B (KQTTK) at the 5 C-terminal-most amino
acid residues (519–523) was identified using the Signal P
algorithm. A mutated construct containing the full length version
of variant B, with a substitution mutation at position 519 (i.e – 4
from the carboxy terminus) of this ER retention motif (K519E)
(Figure 1 B v) did not disrupt localization to the ER (Figure 6).
These observations indicate that the region identified is not
involved in retention of ZnT5 variant B in the ER and that other
differences between the variant A and B carboxy-terminal regions
dictate trafficking to the Golgi apparatus or retention in the ER,
respectively. Work to identify specific residues present in the C-
terminal regions responsible for localization of variant A to the
Golgi apparatus and variant B to the ER is ongoing.
Discussion
Alternative splicing of the ZnT5 gene gives rise to two isoforms
with unique N- and C-termini. It has been noted that variant B
cDNA was not easily generated by RT-PCR from Caco-2 cell
RNA, suggesting a possible low expression level that may only
increase in response to stimulus in specific cell types [13]. Here,
full length ZnT5 variant B is confirmed as a genuine transcript in
Figure 3. Subcellular localization of variants of ZnT5 expressed with a C-terminal GFP tag in HeLa cells. (A) (i)Variant A localizes to the
Golgi apparatus, as revealed by co-localization with Rh-labelled wheat germ agglutinin (WGA) in permeabilized cells. (ii) Variant B localizes to the ER,
as revealed by co-localization with Rh-labelled ER Tracker. (iii) GFP expressed without a protein fusion (negative control). Diagram illustrating C-
terminal fusion constructs of ZnT5 shown alongside. (B) Co transfection of ZnT5 variant B expressed with an N-terminal GFP tag (green) and ZIP7 with
a C-terminal V5 tag (red) showing co-localization to the ER. In merged images shown in A (i) and (ii) nuclei are stained with DAPI (blue).
doi:10.1371/journal.pone.0023878.g003
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Furthermore, using primers specific to the unique 39 sequences in
both variant A and variant B, expression of both isoforms was
confirmed in a range of human tissues by RT-PCR. Although the
data do not allow comparison of absolute ratios, with respect to
differences between tissues, greatest expression of variant B
relative to variant A was detected in bladder, and brain, heart
and adipose tissue also appeared to express variant B at relatively
high levels. The ubiquitous expression of both isoforms would be
consistent with a wide-ranging role for both variant A and variant
B in zinc homeostasis.
Localization of ZnT5 variant A expressed with a C- terminal
GFP or FLAG tag was confirmed at the Golgi apparatus,
consistent with previous reports [10,11], however the same variant
expressed as an N-terminal GFP or FLAG fusion was observed at
the ER, co-localizing with ER Tracker. We propose the presence
of an N-terminal cleavage signal and suggest that the form of
ZnT5 variant A observed in the Golgi apparatus is a mature
cleavage product of a pro-peptide and that the cleaved N-terminal
region is retained in the ER (and so observed here when the GFP
or FLAG tag is at the N-terminus). This model is presented
schematically as Figure 7. Western blot analysis further supports
this theory, with a band of approximately 70–80 KDa being
detected by anti-GFP antibody in protein prepared from cells
expressing the C-terminally tagged construct, whereas the N-
terminally tagged construct was visualized at approximately 40–
55 KDa (consistent with the size of the cleaved N-terminal
fragment plus GFP). A faint band of 110 KDa is visible on this
blot, which could possibly be explained as unprocessed native
protein (Figure 4B). Consistent with this model, it was reported
previously that endogenous ZnT5 variant A protein detected by
immunoblot analysis was smaller than the expected calculated size,
and it was suggested that ZnT5 variant A may be cleaved to yield
a mature protein [10]. Furthermore, recent studies have identified
that ZnT5 variant A expressed heterologously with FLAG fused to
the N-terminus appeared smaller (55 kDa) than the predicted size
(79 kDa) on immunoblot analysis using an anti-hZnT5 antibody
[15]. Our observation agrees with recent evidence provided by
Fukunaka and colleagues who found that a FLAG-tagged N-
terminal deletion mutant of ZnT5 variant A that was complete at
the C-terminus co-localized with HA-hZnT6 to vesicular com-
partments, indicating that the N-terminal region of ZnT5 is not
Figure 4. Subcellular localization of variants of ZnT5 expressed with an N-terminal GFP tag in HeLa cells and expression in HeLa
cells of ZnT5 proteins fused with GFP at either the C- or N- terminus visualized by immunoblotting. (A) (i) Localization of variant A
expressed with GFP fused to the N-terminus was observed at the ER, confirmed by co-localization with Rh-labelled ER Tracker. (ii) Localization of
variant B expressed with GFP fused to the N-terminus was observed at the ER, confirmed by co-localization with Rh-labelled ER Tracker. Diagram
illustrating N-terminal fusion constructs of ZnT5 shown alongside. (B) (i) Immunoblotting using an antipeptide antibody against GFP in cells
expressing variant A with GFP fused to the C-terminus. (ii) Immunoblotting using antipeptide antibody against GFP in cells expressing variant A with
GFP fused to the N-terminus. Approximate band sizes given using comparison to a prestained broad range protein marker (NEB).
doi:10.1371/journal.pone.0023878.g004
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with our current data showing lack of localization of ZnT5 with a
C-terminal deletion, indicate that the C-terminal region must be
involved in targeting the mature peptide to the Golgi apparatus. A
substantial body of evidence is taken to demonstrate that ZnT5
variant A plays a role in the Golgi apparatus to deliver zinc to
nascent zinc-containing proteins, and can act in this capacity as a
functional heterodimer with ZnT6. Such evidence has been
derived from approaches including expression of the recombinant
protein. Such data should be interpreted considering the likelihood
that the functional ZnT5 variant A protein in the Golgi apparatus
results from cleavage of a pro-peptide [13,15,16].
The novel observation that ZnT5 variant B localizes to the ER
raises intriguing questions about a potential role of variant B in
ER-mediated zinc homeostasis. As already noted, ZIP7 has been
localized to the ER membrane and has been predicted to have a
specialised function in transporting zinc from the ER into the
cytosol [14], providing the basis of intracellular zinc signalling
when released as the ‘‘zinc wave’’ [2,3,4,17]. Several pieces of
recent data are suggestive of a mechanism for zinc distribution in
cells, whereby extracellular zinc entering the cell is immediately
buffered within a‘zinc muffler’ and translocated into an
intracellular zinc store, such as the ER [18,19] before ZIP7
releases zinc into the cytosol from the ER [20] in the form of the
‘zinc wave’ [2,3,4]. The identity of the zinc transporter
responsible for the translocation of zinc into the ER from the
‘zinc muffler’ is still unknown. Our novel observation that ZnT5
variant B co-localizes with ZIP7 to the ER, in view of our
previous findings that this transporter can operate both in uptake
and efflux mode [8], suggests that it may fulfill this role [14,17].
Two categories of ER retention/retrieval motifs have been
characterised. The C-terminal tetrapeptide KDEL sequence has
been shown to be necessary for retention of soluble ER-resident
proteins (reviewed by [21]), but is not found in ZnT5. A sequence
almost matching the consensus for a second ER-retention motif
(K (K/Q) XX, when comprising the 4 C-terminal-most amino
acid residues) is present at the C-terminus of ZnT5 variant B
(KQTTK, so deviating from the consensus motif by having an
additional C-terminal residue). Mutation of the lysine reside to
alanine did not affect localization, so the motif appears to be
unrelated to retention in the ER in this case. It is not without
precedence that ER localized proteins include no identifiable or
consensus ER retention motif; for example, subunits of the Sec61
protein are detected to localize to the ER, despite the fact that
none of them contain any known membrane protein retrieval
signal such as cytosolic di-lysine or N-terminal di-arginine motifs
[22]. Furthermore, ZIP7 does not contain an obvious ER
retention motif, apart from ARGL in the N-terminal signal
peptide, which would presumably be cleaved after processing in
the ER [14].
Figure 6. A mutated construct containing the full length version of variant B, with a substitution mutation at position 519 of a
potential ER retention motif (K519E), does not disrupt the ER localization. Diagram illustrating C-terminal fusion construct of ZnT5 shown
alongside.
doi:10.1371/journal.pone.0023878.g006
Figure 5. Correct localization of ZnT5 requires the region 525–666 according to amino acid numbering of Variant A, containing the
histidine-rich segment, plus the C-terminal region specific to variant A or B. (A) Hela cells expressing transiently a construct of ZnT5
representing the region ‘core’ to both variants (amino acids172–666) with a C-terminal GFP tag. The ER is stained (red) with ER Tracker. Note that
localization overlaps with the ER stain, but also includes punctuate structures. Diagram illustrating truncated protein construct 172–666 of ZnT5
shown alongside (B) Hela cells expressing transiently a construct of ZnT5 comprising the region 172 to 524 with a C-terminal GFP tag. In (ii) the ER is
stained (red) with ER Tracker. The inset panel shows the Golgi apparatus stained (red) using WGA. Note that the pattern of localization overlaps with
but is not restricted to the Golgi apparatus or ER. Diagram illustrating truncated protein construct 172–524 of ZnT5 shown alongside.
doi:10.1371/journal.pone.0023878.g005
Differential Subcellular Localization of ZnT5
PLoS ONE | www.plosone.org 7 August 2011 | Volume 6 | Issue 8 | e23878We reported previously localization of ZnT5 to the human
enterocyte apical membrane and to the equivalent location in
polarized human intestinal Caco-2 cells, using an antibody likely
to be cross-reactive with both splice variants [12]. Similarly, we
observed apical membrane localization of heterologously-ex-
pressed, epitope-tagged ZnT5 variant B in polarized Caco-2 cells
[9]. The fact that we observed no plasma membrane localization
of ZnT in HEK293 or HeLa cells in the current study may be
related to a specific localization mechanism that accompanies cell
polarization. We also reported plasma membrane (as well as
diffuse intracellular) localization of ZnT5 variant B based on
heterologous expression of a GFP-tagged protein in CHO cells
[11], pointing towards cell-type or species-specific mechanisms of
localization.
In summary, we present further robust evidence for the
existence of two major splice variants of the SLC30A5 gene,
resulting in ZnT5 variants A and B, and we identify that
differential subcellular localization to the Golgi apparatus and ER
respectively is a function of their alternative C-terminal sequences.
These different C-terminal regions result from the incorporation
into the mature transcript of either the whole of exon 14 (variant
B) or only the 59 region of exon 14 plus exons 15–17 (variant A)
(Figure 1A). We thus propose that exons 15 to 17 include a signal
that results in trafficking of ZnT5 to the Golgi apparatus and that
Figure 7. Schematic diagram of a model for localization of ZnT5. Variant A is expressed as a pro-protein that undergoes cleavage in the ER to
remove an N-terminal signal peptide, which is retained in the ER, while the mature, processed protein trafficks to the Golgi apparatus. In contrast,
variant B is retained in the ER. Thus, when variant A is detected by virtue of a GFP (or epitope) tag attached to the C-terminus, the signal is observed
at the Golgi apparatus (i). If variant A is detected by virtue of a GFP (or epitope) tag attached to the N-terminus, however, the signal is observed at the
ER (ii). In the case of variant B, which does not undergo any proteolytic cleavage, the signal is observed at the ER irrespective of whether the GFP (or
epitope) tag is at the C-terminus (iii) or N-terminus (iv). Retention within the ER/Golgi apparatus requires the region 525 to 666, so a diffuse signal is
observed when the protein is detected by virtue of a GFP (or epitope) tag attached (at either the N- or C-terminus) to a truncated protein lacking this
region (v). Note that there is no intention that the toplogical representation of the protein is accurate.
doi:10.1371/journal.pone.0023878.g007
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ER.
Materials and Methods
Plasmid construction
Full-length cDNA corresponding to ZnT5 splice variant B was
generated by RT-PCR from total RNA extracted from Caco-2
cells by RT-PCR using Velocity DNA polymerase (Bioline) with
primers and thermal cycling parameters as stated in Table 1. For
variant A the plasmid pEGFP-ZnT5A [11] was used (re-named
pZnT5A-GFP (Figure 1B i)), or used as a template for the GFP
fusion at the N-terminus. For expression of full-length ZnT5
variant B with a GFP fusion at the C-terminus the PCR product
was subcloned in-frame into the vector pEGFPN (SacI and ApaI)
(Clontech), to give the plasmid pZnT5B-GFP (Figure 1B v). For
expression of ZnT5 splice variants with a GFP fusion at the N-
terminus PCR products were subcloned in-frame into the vector
pEGFPC (EcoRI and ApaI) (Clontech), to give the plasmids p-
GFPZnT5A (Figure 1B ii) and pGFPZnT5B (Figure 1B vi). Full
length ZnT5 was also subcloned into the FLAG vector (Sigma) to
give the plasmid pFLAG-ZnT5, for expression with an N-terminal
FLAG epitope (NotI and EcoRV), and pZnT5-FLAG, for
expression with a C-terminal FLAG epitope (NotI and EcoRV).
A construct for expression of only the region shared by both splice
variants of ZnT5 (Figure 1B iii) or a shorter shared region minus
the common histidine rich region (Figure 1B iv) with a C-terminal
GFP tag was made using the pZnT5-GFP construct as a template
to generate the required PCR product, using High Fidelity
‘Velocity’ DNA polymersase (Bioline) and primers and thermal
cycling conditions as listed in Table 1, and was then subcloned in
frame into the pEGFPN vector. Correct insert orientation and
sequence fidelity was confirmed by sequencing (MWG Biotech).
The lysine at position 519 of pZnT5B-GFP was mutated to a
glutamate (Figure 1B vii) using the QuikChange Site-Directed
Mutagenesis kit (Stratagene) using primers as listed in Table 1.
The mutated construct was sequenced to confirm successful
mutation (MWG Biotech).
Semi quantitative RT-PCR
ZnT5 variant A and B transcript abundance, in samples of total
RNA prepared from different human tissues (RNA Tissue panel;
Ambion), was measured by semi-quantitative RT-PCR using
primers specific to ZnT5 variant A and variant B as listed in
Table 1. The amplification products from both primer pairs were
sequenced (MWG Biotech) to confirm identity to the expected
products.
Subcelluar localization of GFP-tagged and FLAG-tagged
constructs
For transfection into Hela cells, all plasmid constructs or GFP/
FLAG vector (without insert) were prepared using the EndoFree
Plasmid Maxi kit (Qiagen). Hela cells were grown in Dulbecco’s
modified Eagle’s medium containing 10% fetal calf serum, 1%
non essential amino acids, (all from Sigma) in 6-well plates on glass
coverslips. Cells were transfected 24 h post-seeding, when
approximately 50% confluent, using GeneJammer transfection
reagent (Stratagene), following the manufacturer’s instructions
with a ratio of DNA to GeneJammer of 2 mg:5 ml. Twenty-four
hours post-transfection, cells were stained with 1 mM rhodamine
labelled ER Tracker dye (Molecular Probes) for 30 minutes
according to manufacturer’s instructions and then fixed in 4%
paraformaldehyde (in phosphate-buffered saline) for 30 min at
room temperature, then washed three times with phosphate-
buffered saline. If necessary, cells were permeabilized by treatment
with 0.5% Triton X-100 for 15 min followed by a further wash
with phosphate-buffered saline. Coverslips were mounted in
Vectashield mounting medium (Vector Laboratories Ltd) then
visualized by fluorescence microscopy using an Olympus BX61
fluorescence microscope. In some experiments cells were co-
transfected with pGFP-ZnT5B and ZIP7, expressed as a fusion
protein with a 5 KDa V5 tag on the C-terminal end [14]. V5 was
visualized using an anti V5 monoclonal antibody (1/250, Abcam
ab27671) followed by Alexa Fluor 594-conjugated anti-mouse IgG
secondary antibody (1/1000, Molecular Probes) as previously
described [14].
Table 1. Primers and cycling parameters for PCR.
Product Primer sequence Product Size (bp) Cycling Parameters
ap-GFPZnT5A
201GATGGAGGAGAAATACGGCG
220
2496ATGATGTAAGTACCATCTTTGC
2474
2295 96uC – 30 s, 56uC – 30 s, 72uC – 90 s,
35 cycles
a Variant A cDNA – 39 end
1942GCGGGTGGAGGCATGAATGCTA
1963
2496ATGATGTAAGTACCATCTTTGC
2474
551 95uC – 30 s, 60uC – 30 s, 72uC – 60 s,
25 cycles
a Variant A (172–666)-GFP clone
714CATGGCTAAAATGGCTGAACAC
735
2199CTTTTCTAAAGCAATATGTAGTTCT
2175
1485 96uC – 30 s, 56uC – 30 s, 72uC – 90 s,
35 cycles
a Variant A (172–524)-GFP clone
714CATGGCTAAAATGGCTGAACAC
735
1770TGTTAACATGTGAGTGTCTAATTC
1747
1056 94uC – 30 s, 57uC – 60 s, 72uC – 90 s,
35 cycles
b Full length variant B cDNA/pZnT5B-GFP
1ATGGCTAAAATGGCTGAACAC
22
1569TTTGGTTGTCTGTTTTACTTCCAG
1546
1569 96uC – 30 s, 60uC – 30 s, 72uC – 90 s
35 cycles
b P-GFPZnT5B
1ATGGCTAAAATGGCTGAACAC
22
1569TTTGGTTGTCTGTTTTACTTCCAG
1546
1569 96uC – 30 s, 60uC – 30 s, 72uC – 90 s
35 cycles
b Variant B cDNA – 39 end
1228GCGGGTGGAGGCATGAATGCTA
1249
1569TTTGGTTGTCTGTTTTACTTC
1549
341 94uC – 30 s, 60uC – 30 s, 72uC – 60 s,
30 cycles
Variant B (K519E)
1ATGGCTAAAATGGCTGAACAC
22
1569TTTGGTTGTCTGTTCTACTTCCA
1547
1569 96uC – 30 s, 60uC – 30 s, 72uC – 90 s
30 cycles
Times are given in the order denaturing, annealing, extension and the number of cycles is indicated.
aNumbered according to Genbank
TM sequence NM_022902.
bNumbered according to Genbank
TMsequence JF802034.
doi:10.1371/journal.pone.0023878.t001
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Hela cells expressing either the variant A ZnT5 construct fused
at the C-terminal to GFP or fused at the N-terminal to GFP were
trypsinised and washed in ice cold PBS then lysed in an equal
volume of a buffer containing 60 mM Tris-HCl (pH 6.8), 2%
sodium dodecyl sulphate and 10% glycerol. Total protein was
subjected to SDS-PAGE. Proteins were transferred onto PVDF
membrane (GE Healthcare) and blocked with 5% non-fat milk,
0.025 M Tris pH 8, 0.05 M NaCl, 5% normal horse serum
(Sigma) before incubation with anti-GFP (1:1000) antibodies in
blocking solution overnight at 4uC. Membranes were washed and
incubated for 1 h at room temperature with a horseradish
peroxidase – conjugated goat anti-mouse IgG secondary antibody
(1:5000 dilution) (Sigma). Antibody binding was visualized as
peroxidise activity using ECL-Plus (GE Healthcare) according to
manufacturer’s instructions.
Supporting Information
Figure S1 Subcellular localization of variants of ZnT5
expressed with either a C-terminal or N-terminal FLAG
epitope tag in HeLa cells. (i)Variant A with a C-terminal
FLAG tag (green) localizes to the Golgi apparatus. (ii) Localization
of variant A expressed with FLAG fused to the N-terminus was
observed at the ER (iii) and (vi) Localization of variant B expressed
with either FLAG fused to the C-terminus or N-terminus was
observed at the ER, Diagram illustrating fusion constructs of
ZnT5 shown alongside. In merged images nuclei are stained with
DAPI (blue).
(TIF)
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